[A15-02] Addendum to Commission A14-31 (daclatasvir)
Last updated 19.02.2015
Project no.:
A15-02
Commission:
Commission awarded on 13.01.2015 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A14-31 | Daclatasvir - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2015-02-19 A G-BA decision was published.